Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY   US02043Q1076

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/20/2014 11/21/2014 11/24/2014 11/25/2014 11/26/2014 Date
89.74(c) 91.72(c) 96.18(c) 97.21(c) 100.73(c) Last
359 480 434 542 950 123 510 586 335 070 Volume
+0.19% +2.21% +4.86% +1.07% +3.62% Change
More quotes
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which develops novel therapeutics based on RNA interference.It is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases, including... 
Surperformance© rating of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More about the company
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 36,5 M
EBIT 2014 -369 M
Net income 2014 -356 M
Finance 2014 748 M
Yield 2014 -
Sales 2015 51,5 M
EBIT 2015 -206 M
Net income 2015 -204 M
Finance 2015 676 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 192x
EV / Sales 2015 137x
Capitalization 7 749 M
More Financials
Latest news on ALNYLAM PHARMACEUTICALS, I
1d ago ALNYLAM PHARMACEUTICALS : Presents New Pre-Clinical Data on RNAi Therapeutic Pro..
1d ago ALNYLAM PHARMACEUTICALS : Announces Positive Initial Phase 2 Data with Revusiran..
2d ago ALNYLAM PHARMACEUTICALS : to Webcast Presentations at Upcoming Investor Conferen..
2d ago ALNYLAM PHARMACEUTICALS : Assigned Patent
2d ago ALNYLAM PHARMACEUTICALS : Reports Initial Phase 2 Data with Revusiran (ALN-TTRsc..
11/19 ALNYLAM PHARMACEUTICALS : Expands Hepatic Infectious Disease Pipeline; Adds ALN-..
11/19 ALNYLAM PHARMACEUTICALS : Issues Initial Phase 2 Data with Revusiran (ALN-TTRsc)
11/17 ALNYLAM PHARMACEUTICALS : Presents New Pre-Clinical Data on RNAi Therapeutic Pro..
11/14 ALNYLAM PHARMACEUTICALS : Announces Positive Initial Phase 2 Data with Revusiran..
11/11 ALNYLAM PHARMACEUTICALS : Expands Hepatic Infectious Disease Pipeline; Adds ALN-..
11/11 ALNYLAM PHARMACEUTICALS : Assigned Patent
11/09 ALNYLAM PHARMACEUTICALS : Selects Dr. Pushkal Garg as SVP, Clinical Development
More news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF